Bismuth Containing Quadruple Therapy versus Tailored Therapy as first-line treatments for Helicobacter pylori infection in a high clarithromycin resistance area

• DOI: 10.21203/rs.2.13917/v3
• Publication Date: 2019-11-05T17:00:42Z
• Authors: Byoung Wook Bang; Jong Beom Shin; Eun Jung Ko; Kye Sook Kwon; Yong Woon Shin; Young Ju Suh; Hyungkil Kim; Weonjin Ko
• Keywords: Rapid urease test; Tolerability; Regimen; Esomeprazole; Urea breath test

Abstract Background Increasing clarithromycin resistance has led to the need for an alternative first-line therapy eradication of Helicobacter pylori (H. pylori) in Korea, and bismuth containing quadruple (BQT) tailored (TT) have been proposed as regimens. The aim this study was compare rates BQT TT H. therapies. Methods infection diagnosed using rapid urease test or dual-priming oligonucleotide-based multiplex polymerase chain reaction (DPO-PCR) during endoscopy. Patients positive were divided into two groups; those tested received empirical (the group) whereas by DPO-PCR group). Eradication rates, adverse events, overall medical costs, which included diagnostic regimen compared. Results Three hundred sixty patients (TT group 178, 182). modified intention-to-treat 88.2% (142/161) 80.3% (118/147), respectively (p=0.055), corresponding per-protocol population 88.8% (142/160) 81.4% (118/145) (p=0.07). Compliance event similar groups. Average costs $ 90.3 per patient 75.5 (p=0.000). Conclusions Empirical terms rate, safety, tolerability, but more cost-effective.